CN105031675B - A kind of technique and module for synthesizing Value linear radiopharmaceutical twice in succession - Google Patents
A kind of technique and module for synthesizing Value linear radiopharmaceutical twice in succession Download PDFInfo
- Publication number
- CN105031675B CN105031675B CN201510434051.XA CN201510434051A CN105031675B CN 105031675 B CN105031675 B CN 105031675B CN 201510434051 A CN201510434051 A CN 201510434051A CN 105031675 B CN105031675 B CN 105031675B
- Authority
- CN
- China
- Prior art keywords
- radiopharmaceutical
- value linear
- reaction
- reaction system
- hplc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention belongs to the positron emission sex pill synthesis technical fields of nuclear medicine, and in particular to a kind of technique and module that can once feed, synthesize identical or different 18 radiopharmaceutical of fluorine twice in succession.The technique prepares two groups of leacheates in 18 ion trap of fluorine and release system, two groups of leacheates elute anion trapping column (QMA) respectively in two times, leachates respectively lead to two independent reaction systems by distributing valve twice, separately synthesized 18 radiopharmaceutical of fluorine in each reaction system, the purified processing of 18 radiopharmaceutical of fluorine after synthesis obtain final products.The present invention can meet the requirement of Nuclear Medicine Dept's two kinds of 18 radiopharmaceutical of difference (or identical) fluorine of synthesis in one day in same module, and can improve the utilization rate of equipment, reduce the operating cost of equipment.
Description
Technical field
The invention belongs to the positron emission sex pill synthesis technical fields of nuclear medicine, and in particular to one kind can be filled once
Material, the technique and module for synthesizing identical or different Value linear radiopharmaceutical twice in succession.
Background technology
With the development of PET/CT, clinic needs also to step up to positron emitting tracer.On the one hand it is clinical normal
Rule18F-FDG amounts increase significantly, since the half-life period of Value linear is only 110 minutes, it is therefore desirable to which secondary production can expire more than a day
The clinical needs of foot；Second is that clinical need different Value linear drugs, to meet the requirement of clinical various disease diagnosis, such as it is based on
DNA synthesis18F-FLT, based on cell membrane synthesis18F- monoethyl cholines, the dementia senilis developer based on amyloid proteins18F-
AV45 and based on tumor receptor18F-FES etc..
It is multiple to meet synthesis in one day18F-FDG, GE and Siemens and domestic production man have developed the FDG of 2 times and 4 times respectively
Module.Wherein, the technique of 2 secondary modules of GE is two sets of independent FDG modules, and the FDG modules of Siemens and the country are to use
Piece reaction tube, the technique being used repeatedly.The module of multi-stage synthesis employs the mode of continuous feed liquid, is limited by raw material
System, can only produce single medicine.To meet the requirement of clinical various disease diagnosis, General Electric Apparatus Co.'s (medical system) opens
Fluorine-18 multifunctional automated synthesis module is sent out：Tracer Lab FX F-N, it is more that German Raytest companies develop Value linear
Function Fully automated synthesis module Syn Chrom R＆D, domestic double-tube method fluorine-18 multifunctional module is (see Chinese patent
ZL200910119295.3)；More than fluorine multifunctional module is limited to radioactive residual after operation, and it is primary to be only capable of within one day operation.
If necessary to two different Value linear drugs, independent production in two days is needed, not only wastes the time, but also accelerator is needed to transport
Row is secondary, using secondary target material, wastes resource.Therefore at present all fluorine multifunctional module technique there are it is following not
Foot：
1) after the operation due to radioactive residual, fluorine multifunctional module is only capable of using primary for one day, treat second day it is residual
It after staying radioactive decay, can be reused after manually cleaning, the fluorine-18 multifunctional module including double-reaction tube.If it needs
Two kinds or more drugs are synthesized, two modules need to be equipped with or are produced every other day.
2) it continuously synthesizes single18The module of F-FDG, it is impossible to shared anion trapping column (QMA) capture systems, such as Siemens
Explor 4, have 4 sets of independent QMA systems.GE Tracerlab FX-FDG have 2 sets of independent QMA systems.It can shared QMA
The domestic FDGN modules of capture systems, the elution composition of QMA is the same, and leachates are passed through same reaction tube (see Chinese patent application
200710129912.9), the elution of different requirements can not be met.It can not achieve same QMA, the secondary requirement eluted in batches.
3) due to remaining radioactivity, HPLC piece-rate systems are only capable of using primary in fluorine multifunctional module.
Invention content
It is an object of the invention in view of the drawbacks of the prior art, provide one kind to synthesize two twice in succession in one day
The technique and module of the identical or different Value linear radiopharmaceutical of kind, to make full use of resource, meet clinical requirement.
Technical scheme is as follows：It is a kind of twice in succession synthesize Value linear radiopharmaceutical technique, Value linear from
Two groups of leacheates are prepared in son capture and release system, two groups of leacheates elution QMA (anion trapping column) respectively in two times, two
Secondary leachates respectively lead to two independent reaction systems by distributing valve, and separately synthesized Value linear is put in each reaction system
Penetrating property drug, the purified processing of Value linear radiopharmaceutical after synthesis obtain final products.
Further, the technique for synthesizing Value linear radiopharmaceutical twice in succession as described above, wherein, described two groups of leaching
The water of washing lotion and the ratio of acetonitrile are different, and two groups of leacheates can divide two batches to elute the radioactive substance on QMA into not respectively
Same reaction system.
Further, the volumetric concentration of one group of water is 4~7% (V/V) in two groups of leacheates, another group of water
Volumetric concentration be 7~15% (V/V).
Further, the technique for synthesizing Value linear radiopharmaceutical twice in succession as described above, wherein, by connection valve and
Purification column couples two independent reaction systems, and the intermediary generated in the first reaction system is transferred to
In two reaction systems, complicated Value linear radiopharmaceutical is further synthesized in the second reaction system.
It is a kind of to realize the above-mentioned module for synthesizing Value linear radiopharmaceutical technique twice in succession, including Value linear ion trap and
Release system, the first reaction system, the second reaction system, purification devices, wherein, the Value linear ion trap and release are
System has there are two independent elution bottle, and two leacheates eluted in bottles to elute QMA respectively, and the leachates output pipe of QMA leads to
It crosses triple valve to connect with the first reaction system and the second reaction system respectively, the first reaction system and the second reaction system connect respectively
Connect purification devices.
Further, the module of Value linear radiopharmaceutical is synthesized twice in succession as described above, wherein, described first is anti-
Answering has the first reaction bulb in system, elute the leachates of QMA for the first time and the first reaction system raw material is injected separately into first instead
Answer bottle；There is the second reaction bulb, second of leachates for eluting QMA and the second reaction system are former in second reaction system
Material is injected separately into the second reaction bulb.
Further, it is connected between first reaction bulb and the second reaction bulb by connection valve with purification column, it will
The intermediary generated in first reaction bulb is transferred to the second reaction bulb.
Further, the module of Value linear radiopharmaceutical is synthesized twice in succession as described above, wherein, purifying dress
It puts including performance liquid chromatographic column (HPLC) purification system or purification column；Described performance liquid chromatographic column (HPLC) purification system
In have HPLC in rolling bottle, the first reaction system or the second reaction system generation reactant through rolling bottle in HPLC enter it is same
HPLC purification columns (performance liquid chromatographic column) carry out purification process；In described performance liquid chromatographic column (HPLC) purification system also
With for eluting the acetonitrile bottle of rolling bottle in the HPLC.
Beneficial effects of the present invention are as follows：(1) two independent elution bottle can adjust leaching according to different drugs is synthesized
The ratio of K222/K2CO3 in washing lotion, to reach highest combined coefficient；The ratio of the water and acetonitrile in leacheate can be adjusted,
It in two times will be in radioactive substance elution to two reaction bulbs on same QMA；(2) two independent reaction systems pass through shared
QMA and HPLC can separate independent operating successively and synthesize different Value linear radiopharmaceutical；(3) two independent reaction systems
It can be coupled by connection valve and purification column, the radiopharmaceutical complicated as two-tube multi-functional synthesis.
Description of the drawings
Fig. 1 is the process flow diagram for synthesizing Value linear radiopharmaceutical twice in succession of the present invention；
Fig. 2 is continuous 2 synthesis in specific embodiment18The process flow diagram of F-FDG；
Fig. 3 is continuously to be synthesized in specific embodiment18F-FDG and18The process flow diagram of F-FLT；
Fig. 4 is continuously to be synthesized in specific embodiment18F-FLT and18The process flow diagram of F-AV45；
Fig. 5 is that two reaction system synthesis complexity are combined in specific embodiment18The technological process signal of F-Link- peptides
Figure.
In figure, A. Value linears ion trap and release system, the first reaction systems of B., the second reaction systems of C., D.HPLC are pure
Change system.
X1. leacheate enters the first reaction bulb, and X2. leacheates enter the second reaction bulb, and X3. crude products enter rolling bottle in HPLC, X4.
Connect the first reaction bulb and the second reaction bulb.
1. the first elution bottle, 2. second elution bottles, 3. first reaction bulbs, 4. second reaction bulbs, rolling bottle in 5.HPLC, 6. second
Nitrile bottle, 7.QMA, 8. first reaction system material containers, 9. second reaction system material containers, 10.HPLC purification columns, 11. is useless
Gas, 12. products.
Specific embodiment
The present invention is described in detail below with reference to the accompanying drawings and embodiments.
As shown in Figure 1, two kinds of identical or different Value linear radioactivity can be synthesized twice in succession the present invention provides a kind of
The technique and correlation module of drug, the module are made of four systems, respectively Value linear ion trap and release system A, and first
Reaction system B, second reaction system C, HPLC purification system D (or purification column).Value linear ion trap and release system
Including a six-way valve and QMA, while have there are two independent elution bottle 1,2, acetonitrile and water can be packed into two elution bottles
The different leacheate (identical leacheate can be packed into when preparing identical drug) of ratio, such as the volume of water is packed into elution bottle 1
The leacheate of a concentration of 4~7% (V/V), the leacheate that the interior volumetric concentration for being packed into water of elution bottle 2 is 7~15% (V/V), energy
It is enough to repeat QMA elution in two times；Secondary leachates by distributing valve (triple valve) respectively lead to two independent reaction system B,
C realizes secondary synthesis.Two reaction systems B, C can be independent, be respectively provided with independent sample-adding bottle, different (or the phases of synthesis
Value linear radiopharmaceutical together)；It can also be coupled by connection valve and purification column, the centre that will be completed in the first reaction system B
Object is shifted to the second reaction system C, realizes the chain reaction of two reaction systems B, C, synthesizes complicated Value linear radioactivity medicine
Object.Shared HPLC purification systems D by be used to clean acetonitrile bottle 6, rolling bottle 5 and semipreparative LOOP rings, HPLC are pure in HPLC
Change column 10, radioactivity and UV detector composition；Acetonitrile in acetonitrile bottle 6 can add in rolling bottle 5 in HPLC in batches, in cleaning
Rolling bottle and LOOP rings and HPLC purification columns eliminate the interference of last synthesis；It is formed most after 10 purification process of HPLC purification columns
Whole product 12.
Embodiment 1
The present embodiment produces secondary Value linear ion, continuous quadratic synthesis in same module18F-FDG。
It, can by Value linear ion trap and tri- release system A, the first reaction system B, the second reaction system C system applications
To realize continuous 2 synthesis18F-FDG.As shown in Fig. 2, identical leacheate is packed by bottle 1,2 is eluted, in reaction raw materials container 8
With 9 built-in synthesis18Reagent (acetonitrile, precursor, NaOH and water) needed for F-FDG, it is each between valve V9 and V10 (V20 and V21)
A SEP-PAK C-18 column is filled, V10 and V21 outlets connect purification column (IC-H, Al2O3, C-18 column) respectively.
It synthesizes for the first time：It treats that radioactivity Value linear ion is transferred on QMA 7, starts to synthesize for the first time：With in elution bottle 1
Leacheate Value linear ion is eluted after X1 to the first reaction bulb 3, sequentially add reagent in container 8, product is through V10 to pure
It completes to synthesize for the first time after changing column, obtain18F-FDG。
Second of synthesis：The Value linear ion for treating to produce again is transferred on QMA 7, is started second and is synthesized：With elution bottle
Leacheate in 2 elutes Value linear ion after X2 to the second reaction bulb 4, sequentially adds reagent in container 9, product is arrived through V21
It completes to synthesize for second after purification column, obtain again18F-FDG。
Embodiment 2
The present embodiment realizes Value linear ion of production in same module, continuous to synthesize18F-FDG and18F-FLT。
By Value linear ion trap and release system A, the first reaction system B, second reaction system C, HPLC purification system D
Four systems application can realize continuous synthesis18F-FDG and18F-FLT.It is as shown in figure 3, different by being filled in elution bottle 1,2
Leacheate (mixed liquor of water and acetonitrile), the volumetric concentration of the water of No. 1 leacheate are 5% (V/V), the body of the water of No. 2 leacheates
A concentration of 10% (V/V) of product；8 built-in synthesis of container18Reagent (acetonitrile, precursor, NaOH and water) needed for F-FDG, container 9 is built-in
Synthesis18Reagent (acetonitrile, precursor, HCl and water etc.) needed for F-FLT.
A SEP-PAK C-18 column, V10 connection purification columns (IC-H, Al are filled between valve V9 and V102O3, C-18 columns)
For18The synthesis of F-FDG；A SEP-PAK aluminium column is filled between valve V20 and V21, V21 is through X3 paths and HPLC purifying
The HPLC purification columns connection of system D.
18The synthesis of F-FDG：Treat that radioactivity Value linear ion is transferred on QMA 7, as embodiment 1 starts to close for the first time
Into, unlike, since the volumetric concentration of No. 1 leacheate water is 5% (V/V), the radioactivity on QMA only has 50% to be leached
First reaction bulb 3, program is automatically synthesized, until terminating, is obtained18F-FDG。
18The synthesis of F-FLT：It is 10% (V/V) using the volumetric concentration of No. 2 leacheate water, will all can remains on QMA
Radioactivity is eluted through X2 to the second reaction bulb 4, and program is automatically synthesized, and sequentially adds reagent in container 9, semi-finished product are through valve V21
The rolling bottle 5 into HPLC, detaches through HPLC purification columns 10, obtains18F-FLT completes second and synthesizes.
Embodiment 3
The present embodiment continuously synthesizes in same module18F-FLT and18F-AV45。
By Value linear ion trap and release system A, the first reaction system B, second reaction system C, HPLC purification system D
Four systems application can realize continuous synthesis18F-FLT and18F-AV45.As shown in figure 4, difference will be packed into elution bottle 1,2
Leacheate, 8 built-in synthesis of container18Reagent (acetonitrile, precursor, HCl and water) needed for F-FLT, 9 built-in synthesis of container18F-
Reagent (acetonitrile, precursor, HCl and water etc.) needed for AV45；For being packed into acetonitrile in the acetonitrile bottle 6 of cleaning.
A SEP-PAK aluminium column is filled between valve V9 and V10, V10 is connected by X3 paths with rolling bottle in HPLC 5；
A SEP-PAK aluminium column is filled between valve V20 and V21, V21 is connected through X3 paths with rolling bottle in HPLC 5.Treat radioactive fluorine-
18 ions are transferred on QMA7, and if embodiment 2 starts synthesis 18F-FLT for the first time, semi-finished product are through rolling bottle in valve V10 to HPLC
5, it is detached through HPLC purification columns 10, obtains 18F-FLT, complete to synthesize for the first time.
It completes after synthesizing for the first time, cleans rolling bottle 5 and LOOP rings and HPLC in HPLC with the acetonitrile in acetonitrile bottle 6 and purify
Column 3 times, to eliminate the influence of synthesis for the first time.
The Value linear ion for treating to produce again is transferred on QMA7, when starting second of synthesis, with the elution in elution bottle 2
Liquid elutes Value linear ion after X2 to the second reaction bulb 4, sequentially adds reagent in container 9, semi-finished product are arrived through valve V21
Rolling bottle 5 in HPLC are detached through HPLC purification columns 10, obtain 18F-AV45, are completed second and are synthesized.
The present embodiment can also by adjusting elution bottle 1,2 in leacheate water ratio, realize production Value linear from
Son, it is continuous to synthesize18F-FLT and18F-AV45。
Embodiment 4
The present embodiment combines two complicated drugs of reaction system synthesis in same module18F-Link- peptides.
By Value linear ion trap and release system A, the first reaction system B, second reaction system C, HPLC purification system D
Four systems application can realize the complicated drug of synthesis18F-Link- peptides.As shown in figure 5, elution will be packed into elution bottle 1
Liquid, 8 built-in synthesis of container18Reagent (acetonitrile, precursor, NaOH and water) needed for F- pentynes, 9 built-in synthesis of container18F-Link-
Reagent (nitrine-peptide, catalyst etc.) needed for peptide, treats that radioactivity Value linear ion is transferred on QMA7, starts to synthesize：Elute bottle 1
Interior leacheate elutes Value linear ion into the first reaction bulb 3, sequentially adds reagent in container 8.By the first reaction system B
The raw material of synthesis is evaporated in the second reaction bulb 4 in the second reaction system C, is reacted, then pass through with the raw material in the second reaction bulb 4
The HPLC purification columns 10 of HPLC purification systems D detach, and obtain qualified product18F-Link- peptides.
The present invention, which is realized, carries out necleophilic reactions different twice using two reaction bulbs in same module, synthesizes two kinds
Different drugs.It is anti-to two using the triple valve of a 180 degree by being equipped with the leacheate of two sets of different water and acetonitrile ratio
Bottle is answered to be sequentially transmitted.The leacheate of different proportion can be realized in batches by the Value linear elution to differential responses bottle on QMA
Primary production Value linear ion, secondary use.In addition, HPLC purification columns and separation are cleaned automatically using the acetonitrile in same module
System can detach radiopharmaceutical twice in one day on same HPLC.
Obviously, those skilled in the art can be to the modification and variation on present invention progress various forms without departing from this
The spirit and scope of invention.In this way, if these modifications and changes of the present invention belongs to the claims in the present invention and its equivalent skill
Within the scope of art, then the present invention is also intended to include these modifications and variations.
Claims (7)
1. a kind of technique for synthesizing Value linear radiopharmaceutical twice in succession, it is characterised in that：In Value linear ion trap and release
Two groups of leacheates are prepared in system, two groups of leacheates elute QMA respectively in two times, and leachates are respectively led to by distributing valve twice
Two independent reaction systems, the separately synthesized Value linear radiopharmaceutical in each reaction system, the Value linear radiation after synthesis
Property drug continuously carry out purification process through shared purification devices and obtain final products；During purification process, first by
The Value linear radiopharmaceutical semi-finished product of single sintering are sent to rolling bottle in HPLC, are synthesized through HPLC purification columns isolated first time
Value linear radiopharmaceutical, then clean rolling bottle in HPLC, LOOP rings and HPLC purification columns with acetonitrile, eliminate and close for the first time
Into interference, next the Value linear radiopharmaceutical semi-finished product by second synthesis be sent to rolling bottle in HPLC, through HPLC purification columns
The Value linear radiopharmaceutical of isolated second of synthesis.
2. synthesize the technique of Value linear radiopharmaceutical twice in succession as described in claim 1, it is characterised in that：Described two
The water of group leacheate and the ratio of acetonitrile are different, and two groups of leacheates can divide two batches to elute the radioactive substance on QMA respectively
Enter different reaction systems.
3. synthesize the technique of Value linear radiopharmaceutical twice in succession as claimed in claim 2, it is characterised in that：Described two
The volumetric concentration of one group of water is 4~7% (V/V) in group leacheate, and the volumetric concentration of another group of water is 7~15% (V/V).
4. the technique for synthesizing Value linear radiopharmaceutical twice in succession as described in any one in claim 1-3, feature exist
In：Two independent reaction systems are coupled by connection valve and purification column, will be generated in the first reaction system
Intermediary be transferred in the second reaction system, complicated Value linear radiopharmaceutical is further synthesized in the second reaction system.
5. a kind of module for synthesizing Value linear radiopharmaceutical twice in succession, it is characterised in that：Including Value linear ion trap and release
Place system, the first reaction system, the second reaction system, purification devices, the Value linear ion trap and release system have two
A independent elution bottle, two leacheates eluted in bottles elute QMA respectively, and the leachates output pipe of QMA passes through triple valve
It is connect respectively with the first reaction system and the second reaction system, the first reaction system and the second reaction system connect purifying dress respectively
It puts, the purification devices include performance liquid chromatographic column purification system, have HPLC in performance liquid chromatographic column purification system
The reaction of middle rolling bottle and the acetonitrile bottle for eluting rolling bottle in the HPLC, the first reaction system or the generation of the second reaction system
Object enters same HPLC purification columns through rolling bottle in HPLC and carries out purification process.
6. synthesize the module of Value linear radiopharmaceutical twice in succession as claimed in claim 5, it is characterised in that：Described
In one reaction system there is the first reaction bulb, elute the leachates of QMA for the first time and the first reaction system raw material is injected separately into the
One reaction bulb；There are the second reaction bulb, second of the leachates and the second reaction system for eluting QMA in second reaction system
System raw material is injected separately into the second reaction bulb.
7. synthesize the module of Value linear radiopharmaceutical twice in succession as claimed in claim 6, it is characterised in that：Described
It is connected between one reaction bulb and the second reaction bulb by connection valve and purification column, the intermediary generated in the first reaction bulb is turned
Move to the second reaction bulb.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510434051.XA CN105031675B (en) | 2015-07-22 | 2015-07-22 | A kind of technique and module for synthesizing Value linear radiopharmaceutical twice in succession |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510434051.XA CN105031675B (en) | 2015-07-22 | 2015-07-22 | A kind of technique and module for synthesizing Value linear radiopharmaceutical twice in succession |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105031675A CN105031675A (en) | 2015-11-11 |
| CN105031675B true CN105031675B (en) | 2018-07-03 |
Family
ID=54439028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510434051.XA Active CN105031675B (en) | 2015-07-22 | 2015-07-22 | A kind of technique and module for synthesizing Value linear radiopharmaceutical twice in succession |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105031675B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105662865A (en) * | 2016-04-01 | 2016-06-15 | 原子高科股份有限公司 | [18F] sodium fluoride preparation device |
| CN106098128B (en) * | 2016-08-17 | 2018-07-24 | 天津医科大学总医院 | The hot cell system of radiopharmaceutical is repeatedly produced in short time |
| CN106749435A (en) * | 2016-12-01 | 2017-05-31 | 浙江大学 | A kind of Novel PET probe synthesis system |
| CN107970458A (en) * | 2018-01-03 | 2018-05-01 | 山东省肿瘤防治研究院（山东省肿瘤医院） | A kind of positron emitting tracer Fully automated synthesis module based on 18F-BF3 marks |
| CN114456238A (en) * | 2022-01-26 | 2022-05-10 | 江苏新瑞药业有限公司 | Preparation process and device of alpha-peptide |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2468490Y (en) * | 2000-09-25 | 2002-01-02 | 杜宜奎 | Installation for prodn. of fluorine-18 making drug |
| CN101104627A (en) * | 2007-07-20 | 2008-01-16 | 张锦明 | 18F-FDG automatization synthetic method and device |
| CN101333138A (en) * | 2008-07-23 | 2008-12-31 | 北京师范大学 | Device and process capable of simultaneously preparing three different <18>F radiopharmaceuticals |
| CN102941048A (en) * | 2012-10-30 | 2013-02-27 | 无锡江原安迪科分子核医学研究发展有限公司 | System for automatically synthesizing 18F-FDG |
-
2015
- 2015-07-22 CN CN201510434051.XA patent/CN105031675B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN2468490Y (en) * | 2000-09-25 | 2002-01-02 | 杜宜奎 | Installation for prodn. of fluorine-18 making drug |
| CN101104627A (en) * | 2007-07-20 | 2008-01-16 | 张锦明 | 18F-FDG automatization synthetic method and device |
| CN101333138A (en) * | 2008-07-23 | 2008-12-31 | 北京师范大学 | Device and process capable of simultaneously preparing three different <18>F radiopharmaceuticals |
| CN102941048A (en) * | 2012-10-30 | 2013-02-27 | 无锡江原安迪科分子核医学研究发展有限公司 | System for automatically synthesizing 18F-FDG |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105031675A (en) | 2015-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105031675B (en) | A kind of technique and module for synthesizing Value linear radiopharmaceutical twice in succession | |
| Asti et al. | Validation of 68Ge/68Ga generator processing by chemical purification for routine clinical application of 68Ga-DOTATOC | |
| Dash et al. | Production of 177 Lu for targeted radionuclide therapy: available options | |
| EP2480258B1 (en) | Chemical production module and dose synthesis card for pet biomarker production system | |
| CN101104627A (en) | 18F-FDG automatization synthetic method and device | |
| CN1319599C (en) | RI labelled composition synthesis system | |
| Radchenko et al. | Separation of 90Nb from zirconium target for application in immuno-PET | |
| Kilian et al. | Separation of 44Sc from natural calcium carbonate targets for synthesis of 44Sc-DOTATATE | |
| Boschi et al. | Interdisciplinary tasks in the cyclotron production of Radiometals for medical applications. The case of 47Sc as example | |
| CN108205021A (en) | A kind of detection method of Vonoprazan fumarate in relation to substance | |
| CN107474082A (en) | Double batch PET developers18F FDG pharmaceutical synthesis device and method | |
| CN102430133B (en) | Radioactive medicine synthesis module capable of being repeatedly used in same day | |
| Da Silva et al. | A high separation factor for 165Er from HO for targeted radionuclide therapy | |
| Šrank et al. | Preparation of 90YCl3 radiopharmaceutical precursor for nuclear medicine using technology of centrifugal extractors | |
| CN107108393A (en) | PET indicator purification systems | |
| Sugo et al. | Rapid Flow-Based System for Separation of Radioactive Metals by Selective Complex Formation | |
| US9266084B2 (en) | Automatic synthesizer apparatus for producing radiopharmaceutical tumor imaging agent Gallium-68-DOTATATE and method thereof | |
| KR102490458B1 (en) | Methods for purifying Ga-68 from eluate from 68Ge/68Ga generators and chromatographic columns for use in such methods | |
| Wang et al. | Automated synthesis of hypoxia imaging agent [18 F] FMISO based upon a modified Explora FDG 4 module | |
| Fedorova et al. | Automated Synthesis of [18 F] Fluoromethylcholine for Positron-Emission Tomography Imaging | |
| RU158401U1 (en) | RADIONUCLIDE GENERATOR DEVICE | |
| US20090169439A1 (en) | DEVICE FOR &sup123;I-ADAM AND AUTOMATIC MANUFACTURING DEVICE THEREOF | |
| Fedorova et al. | Automated Optimized Synthesis of [18F] FLT Using Non-Basic Phase-Transfer Catalyst with Reduced Precursor Amount | |
| RU2403641C1 (en) | METHOD OF MAKING CHROMATOGRAPHIC GENERATOR OF TECHNETIUM-99m FROM NEUTRON-IRRADIATED MOLYBDENUM-98 | |
| CN202410235U (en) | Purification column for purifying positron radiopharmaceuticals 18F-FDG (fluorodeoxyglucose) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160819 Address after: 100195, room four, floor 2, building four, West 403, creative garden, Haidian District, Beijing Applicant after: Pat (Beijing) Technology Co., Ltd. Address before: 100853 nuclear medicine, tumor building, 28 Fuxing Road, Beijing, Haidian District Applicant before: Zhou Tong |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |